Martin-Loeches, IgnacioMuriel-Bombín, ArturoFerrer, RicardArtigas, AntonioSole-Violan, JordiLorente, LeonardoAndaluz-Ojeda, DavidPrina-Mello, AdrieleHerrán-Monge, RubenSuberviola, BorjaRodriguez-Fernandez, AnaMerino, PedroLoza, Ana MGarcia-Olivares, PabloAnton, EduardoTamayo, EduardoTrapiello, WysaliBlanco, JesúsBermejo-Martin, Jesús FGRECIA group2023-01-252023-01-252017-04-202110-5820http://hdl.handle.net/10668/11122Pre-evaluation of endogenous immunoglobulin levels is a potential strategy to improve the results of intravenous immunoglobulins in sepsis, but more work has to be done to identify those patients who could benefit the most from this treatment. The objective of this study was to evaluate the impact of endogenous immunoglobulins on the mortality risk in sepsis depending on disease severity. This was a retrospective observational study including 278 patients admitted to the ICU with sepsis fulfilling the SEPSIS-3 criteria, coming from the Spanish GRECIA and ABISS-EDUSEPSIS cohorts. Patients were distributed into two groups depending on their Sequential Organ Failure Assessment score at ICU admission (SOFA  ICU/hospital mortality in the SOFA  Endogenous immunoglobulin levels may have a different impact on the mortality risk of sepsis patients based on their severity. In patients with moderate organ failure, the simultaneous presence of low levels of IgG, IgA and IgM was a consistent predictor of both acute and post-acute mortalities.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/ImmunoglobulinsSepsisSeveritySurvivalresearch article28429310open access10.1186/s13613-017-0268-3PMC5399013https://doi.org/10.1186/s13613-017-0268-3https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399013/pdf